| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/28/2005 | EP1578958A2 Method for suppressing immune system response to transplanted tissue or cells |
| 09/28/2005 | EP1578936A2 Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors |
| 09/28/2005 | EP1578934A2 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 09/28/2005 | EP1578926A2 Novel prostate tumor-specific promoter |
| 09/28/2005 | EP1578922A2 Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| 09/28/2005 | EP1578919A2 Endogenous retrovirus up-regulated in prostate cancer |
| 09/28/2005 | EP1578917A2 Multimeric proteins and methods of making and using same |
| 09/28/2005 | EP1578915A2 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof |
| 09/28/2005 | EP1578912A2 Il-13 mutein proteins, antibodies, compositions, methods and uses |
| 09/28/2005 | EP1578902A2 Neurotransmission-associated proteins |
| 09/28/2005 | EP1578899A2 Secreted proteins |
| 09/28/2005 | EP1578897A2 Process for inducing functional tolerance to gene transfer products |
| 09/28/2005 | EP1578801A2 Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| 09/28/2005 | EP1578799A2 Antibodies directed to tumor necrosis factor and uses thereof |
| 09/28/2005 | EP1578798A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| 09/28/2005 | EP1578782A2 Combination therapy with co-stimulatory factors |
| 09/28/2005 | EP1578779A2 Erythropoietin receptor binding antibodies |
| 09/28/2005 | EP1578773A2 Methods and products based on oligomerization of stress proteins |
| 09/28/2005 | EP1578772A2 Cytokines and cytokine receptors with reduced immunogenicity |
| 09/28/2005 | EP1578771A2 Remodeling and glycoconjugation of peptides |
| 09/28/2005 | EP1578766A2 Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| 09/28/2005 | EP1578760A2 Compositions and methods for the diagnosis and treatment of tumor |
| 09/28/2005 | EP1578480A2 Antagonists for human prolactin |
| 09/28/2005 | EP1578461A2 Vaccines against hiv-1 tat protein to generate neutralizing antibodies |
| 09/28/2005 | EP1578446A2 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 09/28/2005 | EP1578445A2 Therapeutic adjuvant |
| 09/28/2005 | EP1578443A2 Compositions comprising antigen-complexes, method for making same as well as methods of using the antigen-complexes for vaccination |
| 09/28/2005 | EP1578442A1 Novel method for isolating endotoxins |
| 09/28/2005 | EP1578441A2 Polyphosphazene immunocstimulants |
| 09/28/2005 | EP1578439A2 Low dose methods for treating disorders in which tnf-alpha activity is detrimental |
| 09/28/2005 | EP1578434A2 Methods and compositions relating to isoleucine boroproline compounds |
| 09/28/2005 | EP1578432A2 Hla binding peptides and their uses |
| 09/28/2005 | EP1578419A2 Immunostimulatory combinations |
| 09/28/2005 | EP1578396A2 Methods and compositions concerning poxviruses and cancer |
| 09/28/2005 | EP1578394A1 Antibody-containing particles and compositions |
| 09/28/2005 | EP1578385A2 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| 09/28/2005 | EP1578380A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 09/28/2005 | EP1578374A2 Escape mutants of newcastle disease virus as marker vaccines |
| 09/28/2005 | EP1578364A2 Compositions and methods for the treatmentof immune related diseases |
| 09/28/2005 | EP1578362A2 Boroproline compound combination therapy |
| 09/28/2005 | EP1578361A2 Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| 09/28/2005 | EP1578347A2 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 09/28/2005 | EP1578345A2 Peptides and antibodies to muc 1 proteins |
| 09/28/2005 | EP1578305A2 Canine rankl and methods for preparing and using the same |
| 09/28/2005 | EP1578253A2 Prevention and treatment of synucleinopathic disease |
| 09/28/2005 | EP1578199A2 Antigen-presenting cells for neuroprotection and nerve regeneration |
| 09/28/2005 | EP1578197A2 Composition and method for treating lupus nephritis |
| 09/28/2005 | EP1578193A2 Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| 09/28/2005 | EP1267905B1 Composition for the treatment of heart failure |
| 09/28/2005 | EP1263787B1 G-protein coupled receptor |
| 09/28/2005 | EP1137766B1 Use of il-12 antibodies to treat psoriasis |
| 09/28/2005 | EP0991763B1 Modified adenoviral fiber and target adenoviruses |
| 09/28/2005 | EP0912743B1 Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases |
| 09/28/2005 | CN1675542A Isolation and identification of T cells |
| 09/28/2005 | CN1675366A Plastid genetic engineering via somatic embryogenesis |
| 09/28/2005 | CN1675363A T-cell epitopes in staphylococcal enterotoxin B |
| 09/28/2005 | CN1675362A HLA-A24-restricted cancer antigen peptide |
| 09/28/2005 | CN1675353A Substances for preventing and treating autoimmune diseases |
| 09/28/2005 | CN1675240A Variants of the major allergen phl p 1 from timothy grass |
| 09/28/2005 | CN1675237A Immunogenic compositions |
| 09/28/2005 | CN1674936A Treatment of MS with goat serum |
| 09/28/2005 | CN1674935A Biofunctional CpG or oligo-/polynucleotide and toxin or enterotoxin containing composition |
| 09/28/2005 | CN1674934A Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 09/28/2005 | CN1674933A 疫苗组合物 Vaccine compositions |
| 09/28/2005 | CN1674932A Novel bacterium for treatment of disease |
| 09/28/2005 | CN1674931A T cell receptor CDR3 sequences and methods for detection |
| 09/28/2005 | CN1674906A 有丝分裂驱动蛋白抑制剂 Mitotic kinesin inhibitors |
| 09/28/2005 | CN1674878A Immunomodulatory compositions, methods of making, and methods of use thereof |
| 09/28/2005 | CN1673744A Treatment and diagnosis of cancer |
| 09/28/2005 | CN1673372A A novel marnifi blue mold cell wall surface antigen II its coding sequence and application thereof |
| 09/28/2005 | CN1673371A A new marnifi blue mold cell wall surface antigen I, its coding sequence and application thereof |
| 09/28/2005 | CN1673231A Monoclonal antibody of SARS coronavirus N protein and its application |
| 09/28/2005 | CN1672733A HIV-1 treating recombinant chicken pox virus vaccine |
| 09/28/2005 | CN1220521C Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/28/2005 | CN1220484C Microparticles for pulmonary administation |
| 09/27/2005 | US6949628 Detection of infections in humans; obtain sample, incubate with antibody, detect signal, presence of signal indicates infection |
| 09/27/2005 | US6949584 use in inhibiting angiogenesis in a mammal |
| 09/27/2005 | US6949366 Complexing; purified polypeptide |
| 09/27/2005 | US6949345 Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin |
| 09/27/2005 | US6949337 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it |
| 09/27/2005 | US6949246 Monoclonal/polyclonal antibodies for serodetection and treatment of mycobacterium infections |
| 09/27/2005 | US6949244 produced by hybridoma cell line ATCC No. HB 12020; elicits an immune response against (human milk fat globule) HMFG in non-human primates |
| 09/27/2005 | US6949243 administering an anti-SDF-1 or anti-CXCR4 antibody or binding fragment |
| 09/27/2005 | CA2428206C Methods for the treatment of cellular proliferative disorders |
| 09/27/2005 | CA2166718C Vaccine method against swine dysentery |
| 09/27/2005 | CA2149120C Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof |
| 09/27/2005 | CA2099612C Monokine mig induced by ifn-gamma |
| 09/26/2005 | WO2005110452A2 MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS |
| 09/26/2005 | CA2847331A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders |
| 09/26/2005 | CA2847142A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders |
| 09/26/2005 | CA2504868A1 Multiple-variable dose regimen for treating tnf.alpha. related disorders |
| 09/22/2005 | WO2005088307A1 Immunoassays for everolimus |
| 09/22/2005 | WO2005087813A1 Chimeric antigens comprising an fc-fragment for eliciting an immune response |
| 09/22/2005 | WO2005087803A1 A canine vaccine for protection against ehrlichiosis |
| 09/22/2005 | WO2005087796A1 Novel phosphorylated sequences of phosphatase cdc25b, antibodies directed against said sequences and use thereof |
| 09/22/2005 | WO2005087268A1 Axon regeneration promoter |
| 09/22/2005 | WO2005087266A1 Combination therapy for inhibition of platelet aggregation |
| 09/22/2005 | WO2005087265A1 Antineoplastic combinations of cci-779 and rituximab |
| 09/22/2005 | WO2005087264A1 Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| 09/22/2005 | WO2005087263A1 Vaccine for preventing and/or treating a herpes virus infection |